Nina Obertopp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nina Obertopp has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Shari Pilon-Thomas
H. Lee Moffitt Cancer Center & Research Institute
2 shared publications Amy M. Hall
Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
1 shared publicationAshley Thomas
Department of Immunology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
1 shared publicationChristine H. Chung
Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA
1 shared publication- David Basanta
Department of Integrated Mathematical Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, USA
1 shared publication G. Daniel Grass
Department of Radiation Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, USA
1 shared publication
Latest Publications
- Open Access
Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling
Background: The CD3/CD19 bispecific T cell engager (TCE) blinatumomab has shown efficacy in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but response rates are often limited by T cell exhaustion. Recent preclinical studies suggest that incorporating treatment-free intervals (TFIs) into dosing schedules may enhance therapeutic outcomes. Methods: To systematically evaluate alternative TFI strategies, we developed an agent-based model (ABM) of tumor–T cell interactions under various blinatumomab dosing regimens. The model was calibrated using published in vitro data and incorporated spatial, stochastic, and mechanistic rules governing T cell activation, cytotoxicity, proliferation, and exhaustion. Results: Our ABM recapitulates experimental observations showing that a 7-day TFI improved T cell function over continuous dosing during the initial 28-day treatment period. However, when simulations were extended to a full 42-day cycle to mimic clinical regimen, this advantage was lost. In contrast, shorter TFIs consistently outperformed both 7-day and continuous schedules, leading to superior tumor control at all timepoints. A translationally oriented Monday-through-Friday (MO_FR) regimen also achieved comparable benefits. Conclusions: Our results indicate that the empirically tested 7-day TFI schedule may not be optimal. TFI with shorter intervals as well as translationally relevant schedules such as MO_FR, may offer greater therapeutic benefit. This work demonstrates the value of ABM in preclinical immunotherapy design and supports model-guided refinement of TCE dosing strategies prior to clinical translation. Future work will focus on validating these predictions in more complex in vivo models and leveraging patient-derived data to guide personalized TCE treatment design.
Open AccessRethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling
Background: The CD3/CD19 bispecific T cell engager (TCE) blinatumomab has shown efficacy in relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL), but response rates are often limited by T cell exhaustion. Recent preclinical studies suggest that incorporating treatment-free intervals (TFIs) into dosing schedules may enhance therapeutic outcomes. Methods: To systematically evaluate alternative TFI strategies, we developed an agent-based model (ABM) of tumor–T cell interactions under various blinatumomab dosing regimens. The model was calibrated using published in vitro data and incorporated spatial, stochastic, and mechanistic rules governing T cell activation, cytotoxicity, proliferation, and exhaustion. Results: Our ABM recapitulates experimental observations showing that a 7-day TFI improved T cell function over continuous dosing during the initial 28-day treatment period. However, when simulations were extended to a full 42-day cycle to mimic clinical regimen, this advantage was lost. In contrast, shorter TFIs consistently outperformed both 7-day and continuous schedules, leading to superior tumor control at all timepoints. A translationally oriented Monday-through-Friday (MO_FR) regimen also achieved comparable benefits. Conclusions: Our results indicate that the empirically tested 7-day TFI schedule may not be optimal. TFI with shorter intervals as well as translationally relevant schedules such as MO_FR, may offer greater therapeutic benefit. This work demonstrates the value of ABM in preclinical immunotherapy design and supports model-guided refinement of TCE dosing strategies prior to clinical translation. Future work will focus on validating these predictions in more complex in vivo models and leveraging patient-derived data to guide personalized TCE treatment design.
- 27 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (4) , 1102-1115
Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes
- 27 June 2025
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 123 (4) , 1102-1115
Local Single-Dose Radiation Improves Adoptive Cell Therapy With Tumor-Infiltrating Lymphocytes